Immunotherapy for increasing anti-tumour effects has also been considered as a potential route of application for LSD1 inhibition as LSD1 expression is reported as inversely correlated with cytotoxic T cell attracting chemokines along with the programmed death-ligand 1 (PD-L1) in triple-negative breast cancer (TNBC). This evidence concerns the gene KDM1A and triple-negative breast carcinoma.